All.Can – changing cancer care together

All.Can is an international initiative working to improve efficiency in cancer care by focusing on what really matters to patients. For more information, visit the All.Can website.

Context

With the growing prevalence of cancer and ongoing pressures on healthcare budgets, there is a challenge to find sustainable solutions and improve efficiency in cancer care.

Current approaches to cancer care may not be sufficient for tomorrow. We must find new ways to maximise resources, ensuring that the needs of the patient are always at the core of cancer care. This means eliminating elements that bring little or no benefit to patients while prioritising interventions that confer meaningful benefits to patients.

%

20% of healthcare spending is estimated to be wasted on ineffective interventions

Reducing inefficiency could lead to an average gain of 2 life years in industrialised countries

1 in 3 cancer patients don’t receive pain medication appropriate to their pain level

What we achieved

HPP acts as secretariat for All.Can, providing operational support to its Steering Committee and members. Members come from all sectors, including patient organisations, policymakers, healthcare professionals, research and industry representatives.

In addition to All.Can international, there are national All.Can initiatives across Europe, Australia and Canada, with many more in development around the world. They are represented on the international initiative through the National Initiatives Working Group.

All.Can published a policy report in January 2017, which was adapted into a peer-reviewed paper published in the Journal of Cancer Policy. There have been several further All.Can publications and events, including posters at the European Society for Medical Oncology (ESMO) Congress, sessions at the European Health Forum Gastein in 2017 and 2018, and articles in Parliament Magazine, Open Access Government, Brain Tumour Magazine and EuroHealth.

All.Can is currently conducting a patient survey across 11 countries to gain patient insights on where inefficiency occurs across the cancer care pathway. It is also working in partnership with the International Consortium for Health Outcomes Measurement (ICHOM) to look at what contributes to variations in outcomes across lung and breast cancer centres in Europe. Other activities include a research paper exploring the role of data in driving efficiency in cancer care.

All.Can is a collaborating partner of iPAAC, the Joint Action on Cancer Control.

For more information, visit the All.Can website.

Key partners and stakeholders

  • Matti Aapro, Clinique Genolier
  • Tit Albreht, Institute of Public Health, Slovenia
  • Kathleen Barnard, Save You Skin Foundation Canada
  • Birgit Beger, European CanCer Organisation (ECCO)
  • Szymon Chrostowski, Polish Cancer Patient Coalition, Let’s Win Health Foundation
  • David Duplay, Healtheo360
  • Alex Filicevas, European Cancer Patient Coalition
  • Benjamin Gandouet, Oncopole Toulouse

  • Pascal Garel, European Hospital and Healthcare Federation (HOPE)
  • Rainer Hess, GVG-Committee on Health Goals
  • Lydia Makaroff, European Cancer Patient Coalition
  • Zorana Maravic, EuropaColon
  • Rosna Mortuza, International Consortium for Health Outcomes Measurement (ICHOM)
  • Vivek Muthu, Marivek Health Consulting
  • Kathy Oliver, The International Brain Tumour Alliance

  • Richard Price, European CanCer Organisation (ECCO)
  • Natalie Richardson, Save Your Skin Foundation Canada
  • Thomas Szucs, University of Basel
  • Lieve Wierinck, Member of the European Parliament
  • Titta Rosvall-Puplett, Bristol-Myers Squibb
  • Karin Steinmann, Amgen
  • Matthijs van Meerveld, MSD
  • Aleksandra Krygiel-Nael, Johnson & Johnson

The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (lead sponsor), Amgen, MSD and Johnson & Johnson (co-sponsors).